Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

European Journal of Endocrinology

Volumn 174, Issue 2, 2016, Pages 187-192

  Barchetta, I ^a   Alessandri, C ^b   Bertoccini, L ^a   Cimini, F A ^a   Taverniti, L ^a   Di Franco, M ^b   Fraioli, A ^a   Baroni, M G ^c   Cavallo, M G ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b Department of Internal Medicine and Medical Specialties ^*  (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CREATININE; HEMOGLOBIN A1C; INSULIN; OSTEOPONTIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; BLOOD; HYPERTENSION; MIDDLE AGED;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OSTEOPONTIN;

EID: 84956708238     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0791     Document Type: Article

References (33)

1. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC & Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochemistry Journal 1996 317 59-64. (doi:10.1042/bj3170059)
2. Scatena M, Liaw L & Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis Thrombosis and Vascular Biology 2007 27 2302-2309. (doi:10.1161/ATVBAHA.107.144824)
3. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT & Hruska KA. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Molecular Biology of the Cell 2003 14 173-189. (doi:10.1091/mbc.E02-06-0354)
4. Giachelli CM, Lombardi D, Johnson RJ, Murry CE & Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. American Journal of Pathology 1998 152 353-358.
5. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H & Ashkar S. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. Journal of Leukocyte Biology 2002 72 752-761.
6. Crawford HC, Matrisian LM & Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research 1998 15 5206-5215.
7. ORegan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N & Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. Journal of Immunology 1999 162 1024-1031.
8. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ & Cantor H. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000 287 860-864. (doi:10.1126/science.287.5454.860)
9. Ahlqvist E, Osmark P, Kuulasmaa T, Pilgaard K, Omar B, Brøns C, Kotova O, Zetterqvist AV, Stancáková A, Jonsson A et al. Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes 2013 62 2088-2094. (doi:10.2337/db12-0976)
10. Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, Aszmann O, Ludvik B, Silberhumer GR, Prager G et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 2008 149 1350-1357. (doi:10.1210/en.2007-1312)
11. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschöp MH et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Journal of Clinical Investigation 2007 117 2877-2888. (doi:10.1172/JCI31986)
12. Gomez-Ambrosi J, Catalan V, Ramirez B, Rodriguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. Journal of Clinical Endocrinology and Metabolism 2007 92 3719-3727. (doi:10.1210/jc.2007-0349)
13. Ahmad R, Al-Mass A, Al-Ghawas D, Shareif N, Zghoul N, Melhem M, Hasan A, Al-Ghimlas F, Dermime S & Behbehani K. Interaction of osteopontin with IL18 in obese individuals: implications for insulin resistance. PLoS ONE 2013 8 e63944. (doi:10.1371/journal.pone. 0063944)
14. Berezin AE & Kremzer AA. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 2013 229 475-481. (doi:10.1016/j.atherosclerosis.2013.06.003)
15. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q, Fukuda K & Shen W. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 2010 9 70. (doi:10.1186/1475-2840-9-70)
16. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple Sclerosis 2014 20 438-444. (doi:10.1177/1352458513503052)
17. Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa C & Uchiyama S. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. Journal of Neuroimmunology 2013 263 148-151. (doi:10.1016/j.jneuroim.2013.07.005)
18. Comi C, Cappellano G, Chiocchetti A, Orilieri E, Buttini S, Ghezzi L, Galimberti D, Guerini F, Barizzone N, Perla F et al. The impact of osteopontin gene variations on multiple sclerosis development and progression. Clinical and Developmental Immunology 2012 2012 212893. (doi:10.1155/2012/212893)
19. Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR & Bi S. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. Journal of Neuroimmunology 2012 244 94-96. (doi:10.1016/j.jneuroim.2011.12.004)
20. Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S, Suzuki E, Watanabe H & Ohira H. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. International Journal of Rheumatic Diseases 2014 17 50-56. (doi:10.1111/1756-185X.12115)
21. Ji HI, Lee SH, Song R, Yang HI, Lee YA, Hong SJ, Kim S, Park YB, Lee SK, Yoo MC et al. Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clinical Rheumatology 2014 33 397-402. (doi:10.1007/s10067-013-2375-3)
22. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM & Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. Journal of the American Academy of Dermatology 2009 60 225-230. (doi:10.1016/j.jaad.2008.09.046)
23. Xu L, Ma X, Wang Y, Li X, Qi Y, Cui B, Li X, Ning G & Wang S. The expression and pathophysiological role of osteopontin in Graves disease. Journal of Clinical Endocrinology and Metabolism 2011 96 E1866-E1870. (doi:10.1210/jc.2011-1339)
24. Chiocchetti A, Orilieri E, Cappellano G, Barizzone N, D Alfonso S, D Annunzio G, Lorini R, Ravazzolo R, Cadario F, Martinetti M et al. The osteopontin gene C1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population. International Journal of Immunopathology and Pharmacology 2010 23 263-269.
25. Marciano R, DAnnunzio G, Minuto N, Pasquali L, Santamaria A, Di Duca M, Ravazzolo R & Lorini R. Association of alleles at polymorphic sites in the Osteopontin encoding gene in young type 1 diabetic patients. Clinical Immunology 2009 131 84-91. (doi:10.1016/j.clim. 2008.11.004)
26. Gordin D, Forsblom C, Panduru NM, Thomas MC, Bjerre M, Soro-Paavonen A, Tolonen N, Sandholm N, Flyvbjerg A, Harjutsalo V et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 2014 37 2593-2600. (doi:10.2337/dc14-0065)
27. Xu TY, Zhang Y, Li Y, Zhu DL & Gao PJ. The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients. Renal Failure 2014 36 666-672. (doi:10.3109/0886022X.2014. 890002)
28. Hou X, Hu Z, Huang X, Chen Y, He X, Xu H & Wang N. Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients. Journal of Molecular Medicine 2014 92 487-495. (doi:10.1007/s00109-013-1099-9)
29. Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT et al. Proposed international clinical retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003 110 1677-1682. (doi:10.1016/S0161-6420(03)00475-5)
30. Karamizadeh Z, Kamali Sarvestani E, Saki F, Karamifar H, Amirhakimi GH, Namavar Shooshtarian MH & Ashkani-Esfahani S. Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in type 1 diabetes mellitus. Journal of Endocrinological Investigation 2013 36 1090-1093. (doi:10.3275/9098)
31. Bazzichi L, Ghiadoni L, Rossi A, Bernardini M, Lanza M, De Feo F, Giacomelli C, Mencaroni I, Raimo K, Rossi M et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Molecular Medicine 2009 15 402-406. (doi:10.2119/molmed.2009. 00052)
32. Momiyama Y, Ohmori R, Fayad ZA, Kihara T, Tanaka N, Kato R, Taniguchi H, NagataM, Nakamura H & Ohsuzu F. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis 2010 210 668-670. (doi:10.1016/j.atherosclerosis.2009.12.024)
33. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K, Kusuhara M, Nakamura H & Ohsuzu F. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arteriosclerosis Thrombosis and Vascular Biology 2006 26 e1-e2. (doi:10.1161/01.ATV.0000194157.26665.e6)